Navigation Links
Newly designed molecule blocks chlamydia bacteria

DURHAM, N.C. Researchers at Duke University Medical Center have discovered a way to block the damaging actions of Chlamydia, the bacteria responsible for the largest number of sexually transmitted infections in the United States.

The team, which included Duke University microbiologists and chemists, designed a molecule that takes away the bacteria's self-defense mechanisms.

The therapies that could come from this discovery mark a new type of antimicrobial approach. Instead of directly killing the bacteria, they will disarm a central weapon of Chlamydia, and let the body take care of the rest.

Chlamydia infections are symptomless at the beginning, but can become chronic in women and lead to pelvic inflammatory disease and infertility as it infects cells in the uterus and fallopian tubes. It's generally harmless to men. While these infections can be treated with antibiotics, Chlamydia can be easily reacquired and arise as a greater problem again. There are more than nearly 3 million new cases in the U.S. each year.

A virulence factor that Chlamydia produces, called CPAF, emerged as a promising target to shut down because it plays an important role in protecting the bacteria within hiding places (vacuoles) in human cells. CPAF also prevents the human cell from committing suicide when it senses that it has been invaded by a pathogen (a common self-defense mechanism), giving Chlamydia bacteria an extended chance to multiply and stay hidden.

The study was the cover story in the July 21 print edition of Cell Host and Microbe.

Microbiologists and genetics experts led by Raphael Valdivia, Ph.D., an associate professor in the Duke Department of Molecular Genetics and Microbiology, completed the work that narrowed down the search to an enzyme that Chlamydia produces, a protease called CPAF.

"Chlamydia makes this master protease that takes over the whole cell and prevents it from mounting an effective, pathogen-killing immune response," Valdivia said. "Chlamydia is unique among pathogens, in that it can co-exist within humans without causing symptoms for a long time. This reflects a careful balance between the host and the pathogen. We think CPAF is central to this balance. Therefore, if we disarm it, we can tilt the equation toward the human host and mount an effective immune response that will not only clear the infection but prevent it from re-emerging."

The Duke chemists, led by Dewey McCafferty, Ph.D., a professor in the Duke Departments of Chemistry and Biochemistry, designed a molecule that could block the CPAF activity inside of human cells.

"Typically, to design a potent, specific, and cell-permeable inhibitor is a complicated undertaking and inhibitor designs don't work right away," McCafferty said. "But in this case, it worked on the first try. Professor Valdivia's group of microbiologists and my group of chemical biologists worked to establish which qualities we needed to incorporate into a CPAF inhibitor. The results are very exciting, because we have an inhibitor lead molecule that may form the basis for a new class of anti-Chlamydial drugs."

They found that when CPAF was blocked over time by their designed molecule, the protective home that the bacteria make for themselves within the infected cells degraded, and CPAF no longer could degrade the proteins in the cell that would normally mount an immune response to the infection.

When CPAF is inhibited, the infected human cells effectively "commit suicide," Valdivia said. "When the infected human cell dies, so does Chlamydia, and this ends the infection."

Valdivia said that the findings could yield new therapeutic approaches that might turn a natural infection into a vaccination.

"By stopping the cloaking response of the bacteria, we are essentially revealing where they are in the cell and allowing our own immune system to take over and destroy the pathogens," McCafferty said.


Contact: Mary Jane Gore
Duke University Medical Center

Related biology technology :

1. Human Trial Results Show Plant Extract Tops Drug at Regulating Blood Sugar Levels; Huge Market Seen for Newly Developed Food Additive Emulin™
2. Newly Integrated Software Suite From ZS Associates Offers Comprehensive Set of Sales Performance Management Software Solutions
3. China Sky One Medical, Inc. Starts Production at Newly Acquired Facility and Reaffirms Guidance
4. Prometheus Strengthens Intellectual Property Portfolio with Newly Issued Patents for Thiopurine Metabolite Testing
5. Newly Available To Medical Device Manufacturers - Bluetooth Testing Equipment
6. First U.S. Implants of Newly Approved Embozene(TM) Color-Advanced Microspheres Embolization Platform
7. Newly Available To Medical Device Manufacturers - Bluetooth Testing Equipment
8. Hospira Supports Newly Introduced Biogenerics Legislation
9. febit First to Offer Newly Published Mouse Genome on a Chip for DNA/RNA Detection and Enrichment
10. Titanium and Aluminum Distributor, Trans World Alloys Relocates to Its Newly Built, State-of-the-Art Headquarters in Gardena, California
11. RBC Life Sciences Fills Newly Created Vice President of Sales and Marketing Position With Industry Veteran
Post Your Comments:
(Date:11/24/2015)... 2015  Asia-Pacific (APAC) holds the third-largest share ... The trend of outsourcing to low-cost locations is ... volume share for the region in the short ... in the CRO industry will improve. ... ), finds that the market earned revenues ...
(Date:11/24/2015)... 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ... New York on Wednesday, December 2 at 9:30 ... president and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim ... provide a corporate overview. --> th Annual Oppenheimer ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... event of the year and one of the premier annual events for pharmaceutical ... ran from 8–11 November 2015, where ISPE hosted the largest number of attendees ...
(Date:11/24/2015)... 24, 2015 --> ... report "Oligonucleotide Synthesis Market by Product & Services (Primer, ... Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic ... the market is expected to reach USD 1,918.6 Million ... a CAGR of 10.1% during the forecast period. ...
Breaking Biology Technology:
(Date:11/10/2015)... 10, 2015 About signature ... helps to identify and verify the identity of ... as the secure and accurate method of authentication ... particular individual because each individual,s signature is highly ... when dynamic signature of an individual is compared ...
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
Breaking Biology News(10 mins):